Literature DB >> 9839748

The use of the Gompertz function to relate changes in life expectancy to the standardized mortality ratio.

J L Haybittle1.   

Abstract

BACKGROUND: Change in life expectancy may be more readily appreciated by a lay person as a measure of risk than the standardized mortality ratio (SMR).
METHODS: The linear increase in the logarithm of the age-specific mortality rates with age (the Gompertz function) is used to deduce formulae connecting SMR with change in life expectancy. Their validity is checked by a comparison between the 1992 and 1952 mortality data for England and Wales, and between smokers and non-smokers in the American Cancer Society's second Cancer Prevention Study.
RESULTS: It is shown that the Gompertz function is a good fit to mortality data for England and Wales from age 30 years upwards. Changes in life expectancy at ages 15, 25, 45 and 65 are presented for values of SMR from 0.5 to 3. A very simple formula connecting the two is valid at ages 15 and 25, and provides a reasonable approximation at age 45.
CONCLUSIONS: The Gompertz relationship can be used to calculate the change in life expectancy corresponding to a particular SMR over a greater range than have previous methods, and, although subject to some uncertainties, can provide a quick method of judging the change in life expectancy that is associated with a given SMR value.

Entities:  

Keywords:  Age Specific Death Rate; Behavior; Data Adjustment; Data Analysis; Data Quality; Death Rate; Demographic Factors; Developed Countries; England; Europe; Evaluation; Length Of Life; Life Expectancy; Methodological Studies; Mortality; Northern Europe; Population; Population Dynamics; Research Methodology; Smoking; Standardization; United Kingdom; Wales

Mesh:

Year:  1998        PMID: 9839748     DOI: 10.1093/ije/27.5.885

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  7 in total

1.  Life expectancy as a summary of mortality in a population: statistical considerations and suitability for use by health authorities.

Authors:  P B Silcocks; D A Jenner; R Reza
Journal:  J Epidemiol Community Health       Date:  2001-01       Impact factor: 3.710

2.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

3.  Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.

Authors:  Michael Spencer; Andrew H Briggs; Ronald F Grossman; Laureen Rance
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Determining the lifetime density function using a continuous approach.

Authors:  Rubén Román; Mercè Comas; Lorena Hoffmeister; Xavier Castells
Journal:  J Epidemiol Community Health       Date:  2007-10       Impact factor: 3.710

5.  Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population.

Authors:  Wayne C Levy; Kerry L Lee; Anne S Hellkamp; Jeanne E Poole; Dariush Mozaffarian; David T Linker; Aldo P Maggioni; Inder Anand; Philip A Poole-Wilson; Daniel P Fishbein; George Johnson; Jill Anderson; Daniel B Mark; Gust H Bardy
Journal:  Circulation       Date:  2009-08-24       Impact factor: 29.690

6.  Life Expectancy and Years of Potential Life Lost After Acute Myocardial Infarction by Sex and Race: A Cohort-Based Study of Medicare Beneficiaries.

Authors:  Emily M Bucholz; Sharon-Lise T Normand; Yun Wang; Shuangge Ma; Haiqun Lin; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2015-08-11       Impact factor: 24.094

7.  Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials.

Authors:  Wayne C Levy; Dariush Mozaffarian; David T Linker; Kenneth W Kenyon; John G F Cleland; Michel Komajda; Willem J Remme; Christian Torp-Pedersen; Marco Metra; Philip A Poole-Wilson
Journal:  Eur J Heart Fail       Date:  2009-01-22       Impact factor: 15.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.